Vasoconstrictor potency of fixed-dose combination calcipotriol (50 μg/g) and betamethasone dipropionate (0.5 mg/g) cutaneous foam versus other topical corticosteroids used to treat psoriasis vulgaris

C. Queille-RousselCentre de Pharmacologie Clinique Appliquée à la Dermatologie, Nice, France; Correspondence[email protected]
View further author information

J. NielsenLEO Pharma A/S, Ballerup, Denmark; View further author information

J.-P. LacourCentre de Pharmacologie Clinique Appliquée à la Dermatologie, Nice, France; ;Service de Dermatologie, University Hospital of Nice, Nice, FranceView further author information

Citations (4)

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Caitlin G. Purvis, Esther A. Balogh, Courtney E. Heron & Steven R. Feldman. (2021) Topical calcipotriol plus betamethasone dipropionate for the treatment of plaque psoriasis: a drug evaluation. Expert Opinion on Pharmacotherapy 22:9, pages 1107-1118.
Read now

Victoria Amat-Samaranch & Lluís Puig. (2020) Safety of calcipotriene and betamethasone dipropionate foam for the treatment of psoriasis. Expert Opinion on Drug Safety 19:4, pages 423-432.
Read now

Articles from other publishers (2)

Arya K. Ramanunny, Sheetu Wadhwa, Divya Thakur, Sachin K. Singh & Rajesh Kumar. (2021) Treatment Modalities of Psoriasis: A Focus on Requisite for Topical Nanocarrier. Endocrine, Metabolic & Immune Disorders - Drug Targets 21:3, pages 418-433.
Crossref

Y. Tada, L. Iversen & J. Koo. (2021) Early efficacy and safety data with fixed‐dose combination calcipotriol/betamethasone dipropionate foam attributed to mechanism of absorption and steroid potency. Journal of the European Academy of Dermatology and Venereology 35:S1, pages 5-9.
Crossref

Vasoconstrictor potency of fixed-dose combination calcipotriol (50 μg/g) and betamethasone dipropionate (0.5 mg/g) cutaneous foam versus other topical corticosteroids used to treat psoriasis vulgaris

Articles from other publishers (2)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Vasoconstrictor potency of fixed-dose combination calcipotriol (50 μg/g) and betamethasone dipropionate (0.5 mg/g) cutaneous foam versus other topical corticosteroids used to treat psoriasis vulgaris

Citations (4)

Read on this site (2)

Articles from other publishers (2)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date